{'fraction_non_alphanumeric': 0.030448717948717948, 'fraction_numerical': 0.02403846153846154, 'mean_word_length': 5.793478260869565, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Outlook for Implantable Defibrillators

Cardiologists are already familiar with the availability of implantable defibrillators as a treatment for sustained ventricular tachycardia. For two years, abdominally implantable defibrillators have been available from such companies as Guidant (GDT $48), Medtronic (MDT $54), and Ventritex (VNTX $17). However, it seems that cardiologists have not been in a rush to embrace this therapy. The number of transplants worldwide in 1995 was approximately 30,000, whereas the potential market size in sustained ventricular tachycardia patients is probably more than five times that large.